To help researchers more conveniently access validated mRNA and mRNA-tLNP, Enorna officially launches its first batch of ready-to-use mRNA & tLNP off-the-shelf products, providing customers with standardized, high-quality solutions.

EPI-003, has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis B (CHB).